Phase I Trial of CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies
A phase I trial is investigating the efficacy and safety of CD19/CD22 CAR T cells combined with chemotherapy in children and young adults with recurrent or refractory B acute lymphoblastic leukemia.
Phase I
B acute lymphoblastic leukemia
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing phase I trial of CD19/CD22 CAR T cells in pediatric patients represents a significant advancement in the treatment of recurrent or refractory B cell malignancies. Positive outcomes could reshape treatment protocols and enhance Stanford's leadership in CAR T-cell research, influencing future partnerships and funding in this competitive therapeutic area.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results for efficacy and safety outcomes, as well as potential follow-up studies or expansions based on findings.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.